Champions Oncology, Inc. — FY2022 Form 10-K Summary
Reporting period: The filing covers the fiscal year ended April 30, 2022, with FY2021 as the comparable period. This differs from the request metadata’s “2021 Q4”; the filing is an annual report, not a quarterly report. Champions Oncology (Nasdaq: CSBR) is a technology-enabled oncology research company whose revenue is primarily from research services. Its newer businesses include Lumin Bioinformatics SaaS and early-stage drug discovery and development.
Financial results
| Metric | FY2022 | FY2021 | Change |
|---|---|---|---|
| Revenue | $49.1 million | $41.0 million | +19.7% |
| Cost of oncology services | $23.6 million | $21.4 million | +10.2% |
| Gross margin | About 51.9% | About 47.7% | Improved |
| Research and development | $9.4 million | $7.2 million | +30.3% |
| Sales and marketing | $6.4 million | $5.5 million | +15.6% |
| General and administrative | $9.1 million | $6.5 million | +40.0% |
| Operating income | $607,000 | $366,000 | +65.8% |
| Net income | $548,000 | $362,000 | +$186,000 |
| Net income per diluted share | $0.04 | $0.02 | Increased |
Revenue growth was attributed to expanded platforms and product lines and larger in vivo and ex vivo studies. The company reported that lower outsourcing reliance and revenue growth over fixed costs supported improved gross margin. Operating expenses rose 19.2% overall, broadly in line with revenue growth; R&D spending increased as Champions developed service capabilities and drug discovery programs. The MD&A narrative has an apparent wording error describing G&A as a “decrease”; the reported amounts show a 40.0% increase.
Cash flow, liquidity and obligations
- Cash at April 30, 2022 was $9.0 million, compared with $4.7 million a year earlier; working capital was $2.2 million. Accumulated deficit was $72.0 million.
- Operating cash flow was positive $6.5 million, versus negative $1.7 million in FY2021. Management attributed the improvement to cash-based operating results and a $4.8 million increase in deferred revenue, partly reflecting cash received on new studies.
- Investing cash outflow was $2.4 million, primarily for laboratory and computer equipment and software development. Financing cash inflow was $207,000, mainly from option exercises.
- Current liabilities were $17.5 million, including $11.1 million of deferred revenue. Deferred revenue is expected to be recognized within one year. Total assets were $35.4 million and stockholders’ equity was $9.1 million.
- The filing reports no off-balance-sheet debt or similar obligations. Operating lease liabilities totaled $9.5 million ($1.1 million current and $8.4 million non-current); future minimum lease payments were $19.3 million undiscounted.
- Management said cash on hand and expected operating cash flows were adequate to fund operations through at least August 2023, while cautioning that future external capital might be needed and could be unavailable on acceptable terms.
Outlook, risks and notable items
- No quantified revenue, earnings or margin guidance is provided. Management’s stated strategy is to grow its research-services, SaaS and drug-discovery businesses, expand and characterize the TumorBank, and continue investment in experimental and computational platforms. It is evaluating potential strategic options for drug discovery, including a spin-out or capital raise.
- Revenue remains concentrated in research services. Most contracts are terminable by customers, creating cancellation or modification risk. In FY2022, one customer exceeded 10% of revenue and represented 17% of accounts receivable at year-end.
- Key risks include sustained profitability and capital needs; competition and the early stage of SaaS and drug discovery; failure of drug candidates to advance or commercialize; customer study cancellations; regulatory and laboratory compliance; dependence on key personnel and laboratory/mouse operations; intellectual-property protection; cybersecurity; and economic pressures on customers and suppliers.
- The company reported no material adverse COVID-19 impact as of the filing date, but said future effects remained uncertain. It also cited inflation, rising interest rates and geopolitical tensions as potential sources of adverse economic and cyber risk.
- A prior-year material weakness related to review and timely recognition of royalty liabilities was reported as remediated by April 30, 2022. Management concluded internal control over financial reporting and disclosure controls were effective at year-end. The auditor’s critical audit matter was revenue recognition, particularly estimates of project progress and deferred revenue.
- Royalty expense under tumor-model licensing arrangements was $401,000, up from $127,000. The company reported no current legal proceedings and no dividends paid or expected in the foreseeable future. The independent auditor gave an unqualified opinion on the financial statements.
Important facts for investors to verify
- Whether growth in bookings and deferred revenue converts into recognized revenue and cash collections, and whether customer concentration changes.
- Whether improved gross margin and positive operating cash flow are sustainable as R&D, G&A, staffing and facility costs rise.
- Whether management’s stated liquidity runway through at least August 2023 remains valid, including the effect of lease payments and any need for additional financing.
- Progress, commercial prospects and required funding for Lumin and the early-stage drug-discovery pipeline; no specific milestones or financial guidance are provided here.
- Whether the royalty-control remediation remains effective, and how management’s project-progress estimates affect revenue recognition and deferred revenue.